Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

NCT02241785 · clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
47
Enrollment
INDUSTRY
Sponsor class

Stopped Business Decision

Conditions

Interventions

Sponsor

Biogen